BiotechTubeBiotechTube
Home/Pipeline/SL-325

SL-325

Inflammatory Bowel Disease (IBD)

Phase 2Active

Key Facts

Indication
Inflammatory Bowel Disease (IBD)
Phase
Phase 2
Status
Active
Company
Shattuck Labs

About Shattuck Labs

Shattuck Labs is a public biotech company focused on developing novel DR3-targeting antibodies to treat inflammatory diseases, with a primary focus on Inflammatory Bowel Disease (IBD). Its lead program, SL-325, is in Phase 2 development and represents the first clinical-stage DR3 blocking antibody, which the company believes offers potential advantages over competing TL1A-targeting therapies. The company's strategy is built on the scientific premise that blocking the receptor (DR3) rather than the ligand (TL1A) may lead to superior efficacy and reduced immunogenicity. Shattuck is headquartered in the United States with R&D operations in Durham, North Carolina, and a corporate office in Austin, Texas.

View full company profile

Therapeutic Areas

Inflammatory Bowel DiseaseAutoimmune DiseasesInflammatory Diseases

Other Inflammatory Bowel Disease (IBD) Drugs

DrugCompanyPhase
DFTX-201Definium TherapeuticsPreclinical
COSMO-232Cosmo PharmaceuticalsPreclinical
TamuzimodVentyx BiosciencesPhase 2
VTX958Ventyx BiosciencesPhase 2
GPR35 AgonistNxera PharmaPreclinical
SL-425Shattuck LabsPhase 1
ABS-101AbSciPre-clinical
Metabolite Delivery Platform (Therapeutic Programs)ClostraBioPre-clinical
ABO21009AboleIIs PharmaPhase 1